395 related articles for article (PubMed ID: 25801075)
1. Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.
Arandi N; Haghpanah S; Safaei S; Zahedi Z; Ashrafi A; Eatemadfar P; Zarei T; Radwan AH; Taher AT; Karimi M
Transfus Med; 2015 Feb; 25(1):8-12. PubMed ID: 25801075
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
3. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
[TBL] [Abstract][Full Text] [Related]
7. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
[TBL] [Abstract][Full Text] [Related]
8. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
Haghpanah S; Zarei T; Zahedi Z; Karimi M
Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
[TBL] [Abstract][Full Text] [Related]
9. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.
Maggio A; Filosa A; Vitrano A; Aloj G; Kattamis A; Ceci A; Fucharoen S; Cianciulli P; Grady RW; Prossomariti L; Porter JB; Iacono A; Cappellini MD; Bonifazi F; Cassarà F; Harmatz P; Wood J; Gluud C
Blood Cells Mol Dis; 2011 Oct; 47(3):166-75. PubMed ID: 21843958
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
[TBL] [Abstract][Full Text] [Related]
12. Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine.
Grady RW; Galanello R; Randolph RE; Kleinert DA; Dessi C; Giardina PJ
Haematologica; 2013 Jan; 98(1):129-35. PubMed ID: 22875626
[TBL] [Abstract][Full Text] [Related]
13. Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience.
Songdej D; Sirachainan N; Wongwerawattanakoon P; Sasanakul W; Kadegasem P; Sungkarat W; Chuansumrit A
Acta Haematol; 2015; 133(2):226-36. PubMed ID: 25376266
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
Gomber S; Jain P; Sharma S; Narang M
Indian Pediatr; 2016 Mar; 53(3):207-10. PubMed ID: 27029681
[TBL] [Abstract][Full Text] [Related]
15. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
18. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
Karakukcu C; Karakukcu M; Unal E; Patiroglu T; Ozdemir MA; Torun YA; Tang PH
Hemoglobin; 2012; 36(3):219-29. PubMed ID: 22483337
[TBL] [Abstract][Full Text] [Related]
19. A 1-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major.
Eghbali A; Shokri P; Afzal RR; Bagheri B
Transfus Apher Sci; 2019 Aug; 58(4):429-433. PubMed ID: 31229401
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
